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Objectives This study aimed to determine the diagnostic and prognostic value of urinary biomarkers of intrinsic acute kid-
ney injury (AKI) when patients were triaged in the emergency department.
Background Intrinsic AKI is associated with nephron injury and results in poor clinical outcomes. Several urinary biomarkers
have been proposed to detect and measure intrinsic AKI.
Methods In a multicenter prospective cohort study, 5 urinary biomarkers (urinary neutrophil gelatinase–associated lipocalin,
kidney injury molecule-1, urinary liver-type fatty acid binding protein, urinary interleukin-18, and cystatin C) were mea-
sured in 1,635 unselected emergency department patients at the time of hospital admission. We determined
whether the biomarkers diagnosed intrinsic AKI and predicted adverse outcomes during hospitalization.
Results All biomarkers were elevated in intrinsic AKI, but urinary neutrophil gelatinase–associated lipocalin was most useful
(81% specificity, 68% sensitivity at a 104-ng/ml cutoff) and predictive of the severity and duration of AKI. Intrinsic AKI
was strongly associated with adverse in-hospital outcomes. Urinary neutrophil gelatinase–associated lipocalin and
urinary kidney injury molecule 1 predicted a composite outcome of dialysis initiation or death during hospitalization,
and both improved the net risk classification compared with conventional assessments. These biomarkers also identi-
fied a substantial subpopulation with low serum creatinine at hospital admission, but who were at risk of adverse events.
Conclusions Urinary biomarkers of nephron damage enable prospective diagnostic and prognostic stratification in the emergency
department. (J Am Coll Cardiol 2012;59:246–55) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.854t
iAcute kidney injury (AKI) is a common clinical event with
severe consequences. In the United States, 1 million hospi-
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January 17, 2012:246–55 Stratification of Nephron Damage by Urinary Biomarkers80% risk of in-hospital death (4–6) and has been implicated in
the pathogenesis of chronic kidney disease (CKD) (7).
The risk, injury, failure, loss of function, end-stage renal
isease (RIFLE) and the Acute Kidney Injury Network
efinitions of AKI are based on changes in both the levels of
erum creatinine (sCr) and urinary output (8,9). These
efinitions may be problematic, however, when applied to
atients in the emergency department (ED) because the
aseline sCr may be unknown, and placement of a urinary
atheter may not be indicated. Furthermore, subclinical
KI may fail to display diagnostic changes in sCr level
espite evidence of nephron damage (10). Additionally, the
Cr level may not adequately reflect the severity of kidney
njury because sCr kinetics are altered by age, sex, muscle
ass, nutritional status, and medications. Also, the RIFLE
nd Acute Kidney Injury Network definitions do not
onsider the presence of structural nephron damage (intrin-
ic AKI [iAKI]), despite its documented association with
oor clinical outcomes. In fact, sCr levels may meet these
riteria in the absence of nephron damage as a result of
ltered hemodynamics (pre-renal acute kidney injury
pAKI]) (5,11–16).
Some of these shortcomings may be addressed by novel
idney injury biomarkers that are released into the urine after
ellular injury. Currently, the most promising candidates
nclude urinary neutrophil gelatinase–associated lipocalin
uNGAL), urinary kidney injury molecule (uKIM)-1, uri-
ary interleukin (uIL)-18, urinary liver fatty acid binding
rotein (uL-FABP), and urinary cystatin C (uCysC)
17,18). Their diagnostic and prognostic performance has
een evaluated but only in single-center studies, usually
nvolving subtypes of AKI in selected clinical settings. As a
esult, it is unclear: 1) how the biomarkers behave in large,
eterogeneous populations; 2) which biomarker successfully
iscriminates iAKI from either pAKI or CKD, at the time
f patient presentation; and 3) whether combinations of
iomarkers have greater diagnostic accuracy than single
arkers. Urinary biomarkers may provide a strategy to
mprove the diagnosis of iAKI and predict its severity and
linical outcomes beyond currently available tests (16).
long similar lines, a recent meta-analysis suggested that
NGAL identifies a substantial population with subclinical
KI who had escaped detection by sCr measurements but
ho were at increased risk of a poor clinical outcome (19).
To address the comparative utility of urinary biomarkers
o diagnose iAKI and to predict the hospital course, we
onducted this multicenter, prospective, observational study
n a heterogeneous population of ED patients.
ethods
nrollment. The study was conducted at 3 centers: 1) Allen
ospital of New York-Presbyterian Hospital, an inner-city
ommunity hospital including a designated chest pain and
troke center; 2) Staten Island University Hospital, a com-
unity hospital including a designated trauma center, chestain center, and stroke center;
nd 3) Helios Clinics, Berlin-
uch, a community hospital in-
luding a designated trauma cen-
er, chest pain center, and stroke
enter. Recruiting study person-
el, during their work hours, en-
olled all available patients older
han 18 years of age irrespective
f their condition who were in
he process of admission to the
ospital from the ED (Septem-
er 2008 to March 2009). Pa-
ients who had24 h of follow-up
r were on long-term renal re-
lacement therapy were excluded.
ne urine sample was collected
n the ED and medical records
ere accessed. Treating physi-
ians were neither aware of uri-
ary biomarker levels, nor did
ur study hospitals routinely
etermine serum cystatin C lev-
ls. The study was approved by
ach site’s institutional review
oard and performed in com-
liance with the Health Insur-
nce Portability and Account-
bility Act at all study sites.
nformed consent was obtained
rom all participants.
efinitions. This observational
tudy was intended to derive di-
gnostic test characteristics of
rinary biomarkers to predict the
evelopment of inpatient iAKI. Secondary analyses in-
luded severity of AKI, duration of AKI, and a composite
linical outcome of dialysis initiation or mortality. Baseline
Cr was determined by review of the previous 12 months of
ecords, or, if unavailable, baseline sCr was assumed from
he lowest recorded sCr level during the hospital course.
stimated glomerular filtration rate (eGFR) was calculated
sing the Modification of Diet in Renal Disease formula
20).
Diagnostic categorization was performed by adjudicators
ho were blinded to urinary biomarker levels. A priori–
efined algorithms assigned patients to 1 of 4 renal diag-
oses (normal kidney function, stable CKD, pAKI, iAKI).
atients were labeled unclassified when ambiguity occurred
r when disagreement among 2 or more investigators could
ot be resolved by re-evaluation of clinical data.
Definitions of diagnostic categories were applied as fol-
ows. In normal kidney function (n 730), patients met the
ollowing criteria: 1) baseline eGFR 60 ml/min/1.73 m2;
2) failure to meet minimal RIFLE criteria for AKI (8);
Abbreviations
and Acronyms
AKI  acute kidney injury
AUC-ROC  area under the
receiver-operating
characteristic curve
CKD  chronic kidney
disease
ED  emergency
department
eGFR  estimated
glomerular filtration rate
iAKI  intrinsic acute
kidney injury
IDI  integrated
discrimination improvement
NRI  net reclassification
improvement
pAKI  prerenal acute
kidney injury
RIFLE  risk, injury, failure,
loss of function, end-stage
renal disease
sCr  serum creatinine
uCysC  urinary cystatin C
uIL  urinary interleukin
uKIM  urinary kidney
injury molecule
uL-FABP  urinary liver-
type fatty acid binding
protein
uNGAL  urinary neutrophil
gelatinase–associated
lipocalin3) absence of fluctuations in sCr level during the first 3 days
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Stratification of Nephron Damage by Urinary Biomarkers January 17, 2012:246–55of hospitalization (0.3 mg/dl when baseline sCr was 1.0
mg/dl, or 0.2 mg/dl when the baseline sCr was 1.0
mg/dl); and 4) absence of recent exposures to stimuli that
typically cause iAKI (e.g., shock requiring vasopressors,
positive blood cultures, systemic inflammatory response
syndrome or sepsis, nephrolithiasis, recent chemotherapy,
nephrotoxins, rhabdomyolysis, glomerulonephritis, intersti-
tial nephritis, vasculitis, pre-eclampsia, multiple myeloma,
thrombotic microangiopathy). Patients who met criteria 1
and 2, but did not meet criterion 3 or 4 were labeled
unclassified.
In stable CKD (n  154), patients had a baseline eGFR
60 ml/min/1.73 m2 and met criteria 2 to 4 as defined in
ormal kidney function. Patients who met criteria 1 and 2,
ut did not meet criterion 3 or 4 were placed in the
nclassified category.
In pAKI (n  254), patients met the following criteria:
) minimal RIFLE sCr criteria for AKI (1.5-fold increase in
Cr level or 25% decrease in eGFR from baseline; urine
utput criteria were not considered due to difficulty in
btaining accurate measurements in the ED); 2) normalized
alues below the RIFLE-Risk threshold within three days;
) historical and/or clinical data suggesting decreased kidney
erfusion, but no exposure to stimuli, which induce iAKI
see previously); and 4) response to measures to restore renal
erfusion, such as fluid application or diuretic withdrawal.
atients who met criteria 1 and 2, but did not meet criterion
or 4 were labeled unclassified.
In iAKI (n  96), patients met the following criteria:
) minimal RIFLE sCr criteria for AKI; 2) sCr level failed
o normalize below the RIFLE R threshold by 3 days after
dmission; and 3) patients had evidence of exposure to
timuli, which induce iAKI (see previously). Patients who
et criteria 1 and 2, but did not meet criterion 3 or who
ere exposed to factors that may have changed the creati-
ine course subsequent to inclusion (e.g., contrast adminis-
ration in hospital) were labeled unclassified.
aboratory measurements. Urine samples were centri-
uged (12,000 rpm for 10 min) and stored at 80°C within
2 h after patient enrollment. uNGAL, uIL-18, uKIM-1,
nd uCysC were measured by the ARCHITECT platform
Abbott Laboratories, Abbott Park, Illinois) (21). These
ssays used a chemiluminescent microparticle immunoassay
sing a noncompetitive, 2-antianalyte antibody sandwich.
he assays include a microparticle reagent prepared by
ovalently attaching an antianalyte antibody to paramag-
etic particles and a conjugate reagent prepared by labeling
second antianalyte antibody with acridinium. The calibra-
ors for the uNGAL, uIL-18, and uKIM-1 assays were
ecombinant proteins, and the calibrators for the uCysC
ssay were prepared from human urine. The highest cali-
rator for each assay was 1,500 ng/ml, 1 ng/ml, 10 ng/ml,
nd 2500 ng/ml for uNGAL, uIL-18, uKIM-1, and CysC,
espectively. Specimens were diluted to read within the
alibration curve. Coefficients of variation were 3.0% for
NGAL at a 385 ng/ml (21), 2.5% for uKIM-1 at 5.8 pg/ml (Abbott Laboratories), 2.2% for uIL-18 at 0.048
g/ml (Abbott Laboratories), 1.8% for uCysC at 350 ng/ml
Abbott Laboratories), and similar at other cut points.
L-FABP was measured using a sandwich-type enzyme-
inked immunosorbent assay kit (CMIC Co., Ltd., Tokyo,
apan). The coefficient of variation was 6.8% for uL-FABP
t 13 ng/ml (22). Monomeric uNGAL (23 to 26 kDa) was
easured by immunoblots, which were prepared with
onreducing 4% to 15% gradient polyacrylamide gels (Bio-
ad, Hercules, California) using standards (0.3 to 3 ng) of
uman recombinant NGAL and NGAL antibody (Anti-
odyShop, Copenhagen, Denmark). The coefficient of vari-
tion was 5% at different cut points (16). sCr was assayed
t each hospital by the Jaffe reaction, calibrated traceable to
sotope dilution mass spectrometry.
tatistics. Statistical analyses were performed with SAS
ersion 9.2 (SAS Institute, Cary, North Carolina) and SPSS
ersions 16.0 to 19.0 (SPSS, Chicago, Illinois). Sample sizes
ere estimated based on previous data (16) and were
alculated to detect within each study center differences in
iomarker performance among patients with iAKI and
thers (for details, see the Online Appendix). Continuous
ariables were log-transformed and presented as geometric
eans and SDs, where appropriate. Comparisons between 2
onditions were performed using Student’s t test; compari-
ons of 3 or more conditions were performed using analysis
f variance and a post hoc Tukey test. Categorical variables
ere compared by a chi-square test. The null hypothesis was
ejected at p  0.05. Biomarker diagnostic test character-
stics for iAKI were determined by area under the receiver-
perating characteristic curve (AUC-ROC) analysis. For
linical outcomes, univariate logistic regression was used to
dentify independent predictors, including demographic pa-
ameters (age, sex, race), comorbidities (congestive heart
ailure, vascular disease, hypertension, diabetes, human
mmunodeficiency virus, CKD), admission parameters
heart rate, blood pressure, shock index), kidney function
arameters, and study site. Predictors significantly associ-
ted with clinical outcomes from univariate models were
ntered into a multiple logistic regression model, and
ackward selection techniques were used to determine a
aseline risk model. Biomarkers were then sequentially entered
nto the baseline model, including an adjustment for sCr to
etermine independent relationships among the biomarkers
nd the composite clinical outcome. Integrated discrimination
mprovement (IDI) and net reclassification improvement
NRI) were calculated according to Pencina et al. (23).
esults
atient characteristics. We enrolled 1,635 adult patients
resenting to 3 EDs. Site-specific race and ethnic compo-
ition included Berlin (100% white); Staten Island Univer-
ity Hospital (7% Hispanic, 9% black, 79% white, 5%
ther), and Allen Hospital of New York-Presbyterian Hos-
ital (52% Hispanic, 21% black, 27% white). A total of
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January 17, 2012:246–55 Stratification of Nephron Damage by Urinary Biomarkers1,234 (75.5%) patients could be assigned to 1 of 4 diagnostic
categories (normal kidney function, stable CKD, pAKI,
iAKI); 401 patients remained unclassified (Fig. 1). Baseline
characteristics by diagnostic and outcome groups are pre-
sented in Table 1. The primary etiologies of iAKI were
hypotension (34%), urinary obstruction (29%), sepsis (22%),
glomerulonephritis or vasculitis (6%), hepatorenal syndrome
(2.1%), and rhabdomyolysis (2.1%); causes of iAKI present
at a lower prevalence (1%) included contrast nephropathy,
acute interstitial nephritis (biopsy proven), scleroderma
crisis, and multiple myeloma. Seventy-two patients (4.4%)
experienced the composite outcome of dialysis initiation or
death. Causes of death (n  56) included sepsis (n  22;
39%), metastatic cancer (n  9; 16%), heart failure (n  7;
13%), liver failure (n  5; 9%), stroke or intracranial bleed
(n  5; 9%), respiratory failure (n  3; 5%), and gastroin-
Figure 1 Study Flow Chart
Patients from 3 emergency departments were recruited at the time of hospital adm
related with the renal diagnosis and the subsequent hospital course. AH-NYPH 
chronic kidney disease; ESRD  end-stage renal disease; RRT  renal replacement t
interleukin; uKIM  urinary kidney injury molecule; uL-FABP  urinary liver-type fatty actestinal bleed (n  1; 2%). iAKI was strongly associatedwith adverse in-hospital outcomes, including death, dialysis
initiation, and intensive care unit admission (Table 1).
Detection of iAKI. Most patients with iAKI had already
reached their peak RIFLE class on admission (n 62; 64.6%).
Accordingly, both the presenting sCr level and its change from
baseline were significantly higher in iAKI compared with
patients without iAKI (Table 1, Fig. 2). sCr level at presenta-
tion and the ratio of presenting-to-baseline sCr level highly
discriminated iAKI patients (AUC-ROC: 0.91 [95% confi-
dence interval: 0.87 to 0.94] and 0.89 [95% confidence interval:
0.84 to 0.94], respectively) (Table 2). However, presenting sCr
level was not predictive of iAKI when its level was in the
middle tertile of its range (0.9 to 1.2 mg/dl), nor could it
distinguish those patients whose sCr level continued to in-
crease after admission (1.5-fold) from the rest of the cohort.
Furthermore, only 63.5% of the patients had documented
and urine samples were collected. Urinary biomarkers were measured and cor-
ospital of New York-Presbyterian Hospital; AKI  acute kidney injury; CKD 
; SIUH  Staten Island University Hospital; uCysC  urinary cystatin C; uIL  urinary
ing protein; uNGAL  urinary neutrophil gelatinase–associated lipocalin.ission
Allen H
herapy
id bindbaseline sCr values at the time of presentation to the ED,
§
*
te kidn
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Stratification of Nephron Damage by Urinary Biomarkers January 17, 2012:246–55highlighting the difficulties of interpreting single measure-
ments of sCr in triage.
Urinary biomarker levels differed among patients with
iAKI and any other diagnosis (by t test: p  0.001 for all
biomarkers). In addition, subset comparisons showed
Patient Characteristics by Diagnosis and Clinical OutcomeTable 1 Patient Characteristics by Diagnosis and Clinical Outc
Cohort Characteristics Total Cohort
Patients With
Clinical Events
(Death or Dialysis)*
n 1,635 72
Demographics
Age, yrs 64.4 18.7 70.9 16.9§
White 67.6 84.7§
Black 9.5 5.6
Hispanic ethnicity 18.1 6.9§
Female 47.7 58.3
Admission diagnosis
Primary renal disease 0.8 8.3¶
Kidney stones or other
post-renal processes
2.4 1.4
Acute coronary syndrome/
acute myocardial infarction
3.6 0
Decompensated congestive heart
failure
8.2 15.3
Cardiac arrhythmia 3.6 2.8
Sepsis 3.4 15.3¶
Infection without sepsis 22.6 13.9
Liver disease 2.1 11.1¶
TIA or stroke 4.0 8.3
Malignancy 4.8 15.3¶
Admission parameters
Systolic blood pressure, mm Hg 137 27 129 28
Heart rate, min1 88 21 91 25
Shock index 0.8 23.8 29.9
Comorbid conditions
History of CKD (stage 3 or higher)# 25.2 36.1§
Diabetes 29.4 37.5
Hypertension 60.9 69.4
Coronary artery disease 23.2 23.9
Congestive heart failure 27.6 40.8
Peripheral vascular disease 5.6 4.2
Cerebrovascular arterial disease 6.5 8.5
Kidney function
Baseline sCr, mg/dl** 0.9 0.4 1.0 0.6
sCr at admission, mg/dl** 1.1 0.8 1.9 2.3¶
Ratio of change in sCr level from
baseline to admission**
1.2 0.5 1.9 1.8¶
eGFR at admission, ml/min/1.73 m2 70.5 33.2 43.3 30.6¶
Clinical events
Death 3.4 —
In-hospital dialysis initiation 1.5 —
Death without previous dialysis 2.9 —
Death or inpatient dialysis 4.4 —
ICU admission 14.4 —
Values are n, mean  SD, or %. *Compared with patients without clinical events. †Compared wi
p 0.01 (t test or chi-square test, as appropriate). p 0.05 (t test or chi-square test, as appropria
*Geometric mean and SD.
CKD  chronic kidney disease; eGFR  estimated glomerular filtration rate; iAKI  intrinsic acu
TIA  transient ischemic attack.that urinary biomarker levels were significantly elevatedin patients with iAKI compared with each of the other
diagnostic categories (pAKI, stable CKD, or normal
kidney function by 1-way analysis of variance and post-
hoc Tukey test) (Fig. 2). AUC-ROC analyses indicated
good discriminatory ability for uNGAL (AUC-ROC:
tients Without
linical Events
Patients
With iAKI†
Patients With pAKI,
Stable CKD, or
Normal Function
Patients With
Unclear Diagnosis‡
1,563 96 1,138 401
64.1 18.7 67.7 17.6 63.2 18.8 67.0 18.3§
68.7 80.2 68.8 61.9§
9.9 7.3 10.0 8.6
19.1 11.5 18.8 17.8
52.0 47.9 54.4 52.3
0.4 9.4¶ 0.2 0.5
2.4 22.9¶ 0.6 2.5
3.8 2.1 3.7 3.7
7.8 8.3 7.8 9.2
3.7 3.1 3.9 3.0
2.8 15.6¶ 0.9 1.8¶
23.0 17.7 20.5 29.7¶
1.7 9.4¶ 1.6 1.7
3.8 1.0 4.8 2.7
4.3 12.5¶ 4.4 4.0
137 27 129 33 137 26 137 29
88 21 92 21 87 21 90 22
23.5 37.6§ 21.7 26.6
22.6 37.5¶ 19.6 37.0¶
29.0 36.5 25.6 38.3¶
60.5 59.4 59.3 70.0§
23.2 20.8 23.6 22.7
27.0 32.6 24.2 36.0¶
5.7 5.2 5.3 6.6
6.4 5.2 6.2 7.6
0.9 0.4 1.1 0.6¶ 0.9 0.3 1.0 0.5¶
1.1 0.7 2.9 3.4¶ 1.0 0.5 1.2 0.7¶
1.2 0.4 2.5 2.6¶ 1.1 0.3 1.2 0.4
71.7 31.7 28.8 22.1¶ 76.4 31.8 63.6 30.8¶
— 21.9¶ 1.7 4.0
— 17.7¶ 0.3 1.3
— 15.6¶ 1.6 3.5
— 33.3¶ 1.8 4.7
— 29.2¶ 11.8 18.2§
nts with prerenal AKI, stable CKD or normal function. ‡Compared with all adjudicated patients.
 0.001 (t test or chi-square test, as appropriate). #Defined by baseline eGFR60 ml/min/1.73 m2.
ey injury; ICU  intensive care unit; pAKI  prerenal acute kidney injury; sCr  serum creatinine;ome
Pa
C
th patie
te). ¶p0.81), fair discriminatory ability for uKIM-1 and uL-
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poor discriminatory ability for uCysC and uIL-18 (AUC-
ROC: 0.65 and 0.64, respectively) (Online Fig. 1,
Table 2) to distinguish iAKI from other diagnoses. The
AUC-ROC of uNGAL was significantly greater than
that of other urinary markers (p  0.001 each) (Table 2).
When the monomeric form of uNGAL was quantified by
immunoblot, we found that it markedly correlated with
the standardized clinical platform and performed simi-
larly in AUC-ROC analyses (Online Figs. 1 and 2 and
Online Results section). Also, AUC-ROCs remained
similar when biomarker levels were standardized for
urinary creatinine concentrations (data not shown). Sen-
sitivity, specificity, predictive values, and likelihood ratios
for diagnostic cutoffs at the 60th and 75th percentiles for
each biomarker are shown in Table 2. The suggested
cutoff value of uNGAL (104 ng/ml) was similar to a
previously proposed cutoff (16) and meanwhile was vali-
dated in an independent cohort (24).
We performed sensitivity analyses by selecting subsets of
patients based on study site, ethnicity, sex, infection of the
urinary tract, and the co-prevalence of CKD or RIFLE-
AKI. The AUC-ROCs for the diagnosis of iAKI remained
consistent within these subsets (Online Table 1).
Detection of severity and duration of AKI. Given that
iAKI is associated with longer durations and greater severity
of azotemia compared with pAKI (16,25), we performed
secondary analyses to assess the relationship between bio-
marker levels and the duration and severity of AKI. To
evaluate the duration of AKI, the entire cohort was catego-
rized into 3 subgroups: no AKI, transient AKI (defined as
RIFLE-AKI that resolved by 72 h), and sustained AKI
(RIFLE-AKI that persisted for 72 h). Only uNGAL and
uCysC levels were significantly higher in patients with
sustained AKI compared with patients with transient AKI
episodes (Online Fig. 3). Conversely, uKIM-1, uL-FABP,
and uIL-18 were not significantly different in sustained and
transient AKI.
We next stratified the entire cohort by peak RIFLE
severity class (within 7 days from inclusion) (Online Fig. 3).
uNGAL levels progressively and significantly increased in
parallel with RIFLE severity class. In contrast, although the
other biomarkers were higher in RIFLE-AKI than in
non-AKI, these markers did not strictly parallel RIFLE
class. Accordingly, the AUC-ROC for uNGAL progres-
sively increased for the prediction of RIFLE-Risk, RIFLE-
Injury, and RIFLE-Failure, whereas progressive increases
were absent or less pronounced for other biomarkers (On-
line Table 2). Together, these data indicated that uNGAL
was the most powerful indicator of severity and duration of
AKI.
Prediction of clinical events. Patients with iAKI experi-
enced higher rates of a composite clinical outcome of death or
dialysis during hospitalization (Table 1). We used multipleFigure 2 Urinary Biomarker Levels in the Diagnostic
Classification of Emergency Department Patients
uNGAL, uKIM-1, uL-FABP, uIL-18, and uCysC were compared by analysis of vari-
ance in adjudicated patients with normal kidney function (Norm), stable CKD,
pAKI, and iAKI (p values in upper left hand corners of each graph). Biomarkers
differed significantly in patients with iAKI compared with all other adjudicated
groups (*p  0.05, **p  0.01, ***p  0.001 by post-hoc Tukey test). All
diagrams represent geometric means with 95% confidence intervals. iAKI 
intrinsic acute kidney injury; pAKI  prerenal acute kidney injury; sCr  serum
creatinine; Uncl  unclassified; other abbreviations as in Figure 1.logistic regression to construct a conventional baseline predic-
-18; uK
u breviati
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model 1). We then added each individual biomarker to the
baseline model (Table 3, models 2 to 6) and found that each
biomarker added significantly to the predictive ability of the
baseline model. In addition, 2 measures of the overall
performance of the regression model, R2 and AUC-ROC,
improved when each biomarker was added to the baseline
model. We then used stepwise backward selection tech-
niques to identify combinations of biomarkers that inde-
Test Characteristics of Urinary Biomarkers in the Diagnosis of iAKIPredictive Values, and Likelihood RatiosTable 2 Test Characteristics f U inary Biomarkers in the DiagPredictive Values, and Likelihood Ratios
Urinary
Biomarker
AUC-ROC
(95% CI)
Cutoff Level,
ng/ml
Sensitivity,
%
Specifi
%
uNGAL 0.81 (0.76–0.86) 104 68 81
47 82 67
uKIM-1 0.71 (0.65–0.76)* 2.817 52 79
1.665 63 65
uIL-18 0.64 (0.57–0.70)† 0.065 43 78
0.036 58 65
uL-FABP 0.70 (0.65–0.76)† 12.9 50 80
5.2 67 66
uCysC 0.65 (0.58–0.72)† 171 46 80
101 59 64
sCr 0.90 (0.86–0.93) 1.4 81 82
1.1 92 63
2 cutoff values were analyzed for each urinary biomarker, corresponding to the 60th (lower cutof
0.0001 vs. uNGAL. ‡Positive likelihood ratio  sensitivity/(1  specificity). §Negative likelihood r
AUC-ROC  area under the receiver-operating characteristic curve; uIL-18  urinary interleukin
NGAL  urinary neutrophil gelatinase–associated lipocalin; uCysC  urinary cystatin C; other ab
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***p  0.001, **p  0.01. Abbreviations as in Figures 1 and 2.pendently contributed to the prediction of the composite
outcome. We found that uNGAL and uKIM-1 indepen-
dently added to a combined prediction model (Table 3,
model 7). However, R2 and AUC-ROC of the combined
model increased only slightly compared with the single
biomarker models.
To examine the incremental utility of urinary biomark-
ers and their combinations in more detail, we calculated
the IDI, comparing the biomarker-aided models (models
ding AUC-ROC Analysis,of iAKI Including AUC-ROC Analysis,
Positive Predictive
Value, %
Negative Predictive
Value, %
Positive
Likelihood
Ratio
Negative
Likelihood
Ratio
23 97 3.64 0.39
17 98 2.49 0.27
17 95 2.49 0.61
12 95 1.76 0.58
14 94 1.95 0.73
12 95 1.67 0.64
18 95 2.56 0.62
14 96 1.90 0.50
16 95 2.26 0.68
12 95 1.70 0.60
28 98 4.49 0.23
17 99 2.48 0.13
5th (upper cutoff) percentiles of the biomarker level across the entire cohort. *p  0.001. †p 
(1  sensitivity)/specificity. Serum creatinine (sCr) is shown for comparison.
IM-1  urinary kidney injury molecule 1; uL-FABP  urinary liver-type fatty acid binding protein;
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This method compares the risk estimates derived from
each model in patients with outcomes (events) and in
patients without outcomes (nonevents). A biomarker-
aided risk estimate will achieve a positive IDI compared
with a conventional risk estimate, if patients with events
are assigned higher risk estimates and if patients without
events are assigned lower risk estimates. The data showed
that uNGAL- and uKIM-1–assisted models achieved
significant IDIs compared with the baseline model (Table 3).
The uNGAL-assisted model also achieved a significant IDI
compared with models using uL-FABP, uIL-18, or CysC
(models 4, 5, and 6) (p  0.05 each). A triple model of sCr,
NGAL, and uKIM-1 (model 7) did not achieve a signif-
cant IDI compared with the double model with sCr and
NGAL (Table 3). These data indicated that uNGAL and
KIM-1 individually improved risk stratification when
ombined with sCr level, whereas a combination of uN-
AL and uKIM-1 did not further improve the predictive
bility.
To estimate the NRI facilitated by uNGAL and
KIM-1, we defined 3 risk categories (2%, 2% to 15%,
nd 15%) of experiencing the composite outcome within
ur ED population, which were based on the expected rates
f in-hospital mortality and in-hospital dialysis initiation
16). Next, we assigned each patient to one of these risk
lasses based on either the biomarker-assisted models
Multivariate Logistic Regression Analysis of Urinary Biomarkers inPred ction of the Composite Outcome (In-Hospital Dialysis InitiatioTable 3 Multivariate Logistic Regressi n An ys s f U i ary BiPrediction of the Composite Outcome (In-Hospital Dial
Covariates*†
Model 1
RSQ 0.08
AUC-ROC 0.72
Model 2
RSQ 0.12
AUC-ROC 0.75
IDI‡ 0.022§
Model 3
RSQ 0.12
AUC-ROC 0.76
IDI‡ 0.017
sCr 3.14 (1.91–5.14) 2.58 (1.54–4.30) 2.79 (1.67–4.65)
uNGAL 3.03 (1.83–5.02)
uKIM-1 3.15 (1.90–5.23)
uIL-18
uL-FABP
uCysC
*All cutoffs at the 75% percentile; values represent exp(B) (the change in the odds ratio associat
for age, admission parameters, comorbidities, and location. ‡IDI vs. model 1. §p  0.001. p  0
IDI  integrated discrimination improvement; RSQ  Nagelkerke R2; other abbreviations as in
Net Reclassification Improvement as Facilitated by Biomarker-AideTable 4 Net Reclassification Improvement as Facilitated by Bio
Patients Appropriately
Reclassified
uNGAL-assisted (model 2) vs. baseline (model 1)
Nonevents 245 (16.0)
Events 18 (25.4)
uKIM-1-assisted (model 3) vs. baseline (model 1)
Nonevents 303 (19.9)
Events 14 (20.9)
Values are n (%) or %. Individual probabilities of experiencing the composite outcome were calcul
2 and 3; Table 3) to stratify patients into 3 risk classes (2%, 2% to 15%, 15%). Appropriate
step-down in risk class in patients without events, whereas inappropriate reclassification was vice versa.
Abbreviations as in Table 2.(model 2 or 3) or the conventional model (model 1). The
net number of patients with a classification improvement
after uNGAL-stratified assessment was 120 (7.8%) among
patients without events and 13 (18.3%) among patients with
events (Table 4). The net number of patients with a
classification improvement after uKIM-1–stratified assess-
ment was 204 (13.4%) among patients without events and 7
(10.4%) among patients with events (Table 4). Hence, the
introduction of uNGAL and uKIM-1 facilitated NRI of
26.1% and 23.8%, respectively.
To translate these findings into a diagnostic strategy,
we risk stratified patients by sCr level and used uNGAL
or uKIM-1 to further subdivide these categories. Based
on 75th percentile cutoffs, we separated patients into
sCr (sCr 1.4 mg/dl) and sCr (sCr 1.4 mg/dl) at
he time of inclusion. We then subdivided sCr and sCr
patients into biomarker positive (biomarker  cutoff at
75th percentile) or biomarker negative (biomarker
 cutoff at 75th percentile). Event rates within sCror
sCr patients were substantially different depending on
hether they were biomarker positive or biomarker
egative (Fig. 3). In particular, approximately 15% of the
opulation had a low sCr level, but high biomarker levels,
lacing them at low risk by conventional stratification,
ut at an increased risk on application of biomarker-aided
tratification.
ortality)ke s in the
nitiation or Mortality)
Model 4
RSQ 0.10
UC-ROC 0.73
IDI‡ 0.010
Model 5
RSQ 0.10
AUC-ROC 0.74
IDI‡ 0.010
Model 6
RSQ 0.10
AUC-ROC 0.74
IDI‡ 0.004 (NS)
Model 7¶
RSQ 0.14
AUC-ROC 0.77
IDI# 0.008 (NS)
1 (1.95–5.29) 2.73 (1.64–4.53) 2.64 (1.57–4.45) 2.40 (1.42–4.05)
2.43 (1.42–4.16)
2.54 (1.50–4.30)
7 (1.19–3.25)
2.19 (1.33–3.61)
2.11 (1.26–3.53)
the predictor variable), with 95% confidence intervals. †All multiple logistic models are adjusted
tepwise selection model including sCr, uNGAL, uKIM-1, uIL-18, uL-FABP, uCysC. #IDI vs. model 2.
1 and 2.
diction Modelser-Aided Prediction Models
ients Inappropriately
Reclassified
Net No. of Patients With
Classification
Improvement
Net Reclassification
Improvement, %
125 (7.8) 120 (7.8)* 26.1*
5 (7.0) 13 (18.3)†
99 (6.5) 204 (13.4)* 23.8*
7 (10.4) 7 (10.4)
cording to the baseline model (model 1; Table 3) and to the biomarker-assisted models (models
ker-assisted reclassification was defined as a step-up in risk class in patients with events and athen or Momar
ysis I
A
3.2
1.9
ed withd Premark
Pat
ated ac
biomar*p  0.001. †p  0.01.
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This is the first multicenter study to comprehensively
compare the diagnostic and predictive abilities of urinary
biomarkers. Our goals were to evaluate their ability to:
1) distinguish iAKI from pAKI, stable CKD, and normal
kidney function; and 2) facilitate a prospective risk assess-
ment regarding a requirement for dialysis or the death of the
patient during subsequent hospitalization.
Every patient who entered the ED and was subsequently
hospitalized for 24 h was included in the study. Although
the exclusion of patients hospitalized for 24 h may have
introduced some bias in favor of sicker patients compared
with the inclusion of all comers, derivation of the test
characteristics of biomarkers compared with standard clin-
ical information necessitated a reasonable period in which to
accumulate follow-up data.
Our study was limited by the absence of a diagnostic gold
standard of iAKI. We addressed this limitation by estab-
lishing a standardized adjudication procedure to define
iAKI, which was based on sCr dynamics, the etiology of
AKI, and the response to therapy considering kidney
physiology in addition to AKI pathogenesis (16). Using this
strict approach, we could analyze three fourths of the cohort
without ambiguity, but because we could not assign a
definitive diagnosis to approximately one fourth, we per-
formed adjudication-independent secondary analyses across
the entire cohort and found these approaches to be com-
plementary: the utility to diagnose iAKI in a strictly defined
cohort paralleled the biomarkers’ ability to predict the
intensity and duration of AKI in all comers. For instance,
uNGAL performed significantly better than the other
biomarkers in diagnosing iAKI, and consistently uNGAL
displayed a closer association with severity and duration of
AKI compared with the other biomarkers. Importantly,
uNGAL was progressively more effective in predicting
increasing RIFLE classes, a finding consistent with previous
studies (26,27).
It is noteworthy that both the presenting sCr level and its
change from baseline highly discriminated iAKI patients
from other diagnostic groups. This may in part be related to
the fact that sCr level was a major determinant of the
diagnostic adjudication procedure itself and that most pa-
tients had already achieved their peak RIFLE severity class
at presentation to the ED. This also implies that urinary
biomarkers will be most useful when sCr dynamics are
unknown or when the sCr level is in the middle of its range.
Our study confirmed the known association of the type of
AKI with the clinical outcome. Although 4% of patients
with normal kidney function, stable CKD, or pAKI expe-
rienced the composite outcome of in-hospital mortality or
the requirement to initiate in-hospital hemodialysis, 33.5%
of the patients with iAKI experienced this outcome. Several
smaller studies linked high urinary biomarker levels with
these unfavorable clinical events (16,28–31), and here we
confirmed this association. However, our large sample sizeenabled us to characterize the contribution of each bio-
marker; uNGAL and uKIM-1 were the most accurate
predictors of subsequent clinical events, and each markedly
improved risk assessment when combined with the conven-
tional sCr-assisted prediction models, as determined by IDI
and NRI. In contrast, the combination of uNGAL and
uKIM-1 did not further improve risk classification, nor were
we able to find evidence of the superiority of 1 of the 2
markers in head-to-head comparisons.
Study limitations. Besides the issues discussed above,
there are additional limitations to this study. Even with the
biomarker-aided improvement in risk stratification, we can-
not assess its potential implications for clinical management
without a prospective randomized trial. Also, most of the
biomarkers were assayed using single clinical assays, except
for uNGAL, where we were able to determine the molec-
ular identity of the AKI-specific NGAL monomer using
immunoblots and correlating these findings with an estab-
lished clinical platform. However, we were unable to achieve
a comparable molecular assessment of the other biomarkers.
For each biomarker, the diagnostic and prognostic utility
may be different when other clinical platforms are used.
Conclusions
In summary, we characterized the performance of different
urinary biomarkers obtained on patient entry to the hospital
to diagnose iAKI (as defined by strict criteria) and to
determine its severity and clinical sequelae. Our analysis
prospectively validated the concept that the addition of
urinary biomarkers and their interpretation together with
sCr levels identified patients at risk who otherwise would
have been missed during triage.
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